Literature DB >> 14754898

Directed in vitro evolution and crystallographic analysis of a peptide-binding single chain antibody fragment (scFv) with low picomolar affinity.

Christian Zahnd1, Silvia Spinelli, Béatrice Luginbühl, Patrick Amstutz, Christian Cambillau, Andreas Plückthun.   

Abstract

We generated a single chain Fv fragment of an antibody (scFv) with a binding affinity of about 5 pm to a short peptide by applying rigorous directed evolution. Starting from a high affinity peptide binder, originally obtained by ribosome display from a murine library, we generated libraries of mutants with error-prone PCR and DNA shuffling and applied off-rate selection by using ribosome display. Crystallographic analysis of the scFv in its antigen-bound and free state showed that only few mutations, which do not make direct contact to the antigen, lead to a 500-fold affinity improvement over its potential germ line precursor. These results suggest that the affinity optimization of very high affinity binders is achieved by modulating existing interactions via subtle changes in the framework rather than by introducing new contacts. Off-rate selection in combination with ribosome display can evolve binders to the low picomolar affinity range even for peptide targets.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14754898     DOI: 10.1074/jbc.M309169200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Attainment of 15-fold higher affinity of a Fusarium-specific single-chain antibody by directed molecular evolution coupled to phage display.

Authors:  Jin-Long Liu; Zu-Quan Hu; Shu Xing; Sheng Xue; He-Ping Li; Jing-Bo Zhang; Yu-Cai Liao
Journal:  Mol Biotechnol       Date:  2012-10       Impact factor: 2.695

2.  MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

Authors:  Surender Khurana; Nitin Verma; Jonathan W Yewdell; Anne Katrin Hilbert; Flora Castellino; Maria Lattanzi; Giuseppe Del Giudice; Rino Rappuoli; Hana Golding
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

Review 3.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

4.  Chemically Programmable and Switchable CAR-T Therapy.

Authors:  Junpeng Qi; Kohei Tsuji; David Hymel; Terrence R Burke; Michael Hudecek; Christoph Rader; Haiyong Peng
Journal:  Angew Chem Int Ed Engl       Date:  2020-05-18       Impact factor: 15.336

Review 5.  Laboratory-directed protein evolution.

Authors:  Ling Yuan; Itzhak Kurek; James English; Robert Keenan
Journal:  Microbiol Mol Biol Rev       Date:  2005-09       Impact factor: 11.056

6.  A label-free immunosensor array using single-chain antibody fragments.

Authors:  Natalija Backmann; Christian Zahnd; Francois Huber; Alexander Bietsch; Andreas Plückthun; Hans-Peter Lang; Hans-Joachim Güntherodt; Martin Hegner; Christoph Gerber
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-28       Impact factor: 11.205

7.  Electrostatic properties of protein-protein complexes.

Authors:  Petras J Kundrotas; Emil Alexov
Journal:  Biophys J       Date:  2006-06-16       Impact factor: 4.033

8.  Affinity-matured recombinant antibody fragments analyzed by single-molecule force spectroscopy.

Authors:  Julia Morfill; Kerstin Blank; Christian Zahnd; Beatrice Luginbühl; Ferdinand Kühner; Kay-E Gottschalk; Andreas Plückthun; Hermann E Gaub
Journal:  Biophys J       Date:  2007-08-03       Impact factor: 4.033

9.  Synthetic antibody libraries focused towards peptide ligands.

Authors:  Christian W Cobaugh; Juan C Almagro; Mark Pogson; Brent Iverson; George Georgiou
Journal:  J Mol Biol       Date:  2008-03-04       Impact factor: 5.469

10.  Directed evolution of a fluorogen-activating single chain antibody for function and enhanced brightness in the cytoplasm.

Authors:  Bradley P Yates; Michelle A Peck; Peter B Berget
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.